Rene Bernards

Kathryn Wellen

René Bernards’ laboratory uses functional genomic approaches to find vulnerabilities of cancers that can be exploited therapeutically. Using the concept of synthetic lethality, his laboratory searches for combinations of drugs that are lethal for cancer cells and for vulnerabilities of cancer cells of a defined genotype. As one example, his laboratory identified the combination of a BRAF inhibitor and an EGFR inhibitor as effective for the treatment of BRAF mutant colon cancer. There are currently eleven clinical trials ongoing that test the efficacy of the cancer therapies suggested by genetic screens from his laboratory.